Thanks for visiting Imaging and Machine Vision Europe.

You're trying to access an editorial feature that is only available to logged in, registered users of Imaging and Machine Vision Europe. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Acoustic imaging shows promise for early diagnosis of tumours

Share this on social media:

Recent results from the Engineering Science Department of the University of Oxford have demonstrate the effectiveness of its Oxford Electromagnetic Acoustic Imaging (OxEMA) technology. OxEMA is a healthcare imaging technology offering superior diagnostic power to conventional ultrasound systems and MRI-like images.

The results showed that OxEMA clearly identifies artificially introduced abnormalities (mimicking a stone and tumours), in a sheep's kidney, which are not clearly differentiated using conventional ultrasound.

OxEMA's technology uses a combination of electro-magnetic and acoustic waves in order to create medical images at a cost comparable to ultrasound. The benefits of this are much greater clarity of image and excellent tissue-type characterisation in this price bracket. The technology is non-ionising and thus offers a clear benefit over x-ray and CT scanning.

OxEMA has the potential to enable better, earlier diagnosis of numerous conditions and tumours, including some or all of breast, liver, kidney and thyroid cancer, as well as having applications in orthopaedics and other clinical areas. The technology provides an automatically registered, overlaid EMA image on top of the ultrasound image, providing the ability to simultaneously assess the electrical and mechanical properties of the same piece of tissue, with considerably improved diagnostic power.

Professor David Edwards, who leads this research at the Department of Engineering Science, said: 'OxEMA has the capability of producing MRI-like images, because it utilises the electromagnetic properties of tissue as the contrast mechanism. Using the electromagnetic signature of the identified targets, the technology has the potential to be used in the classification and identification of specific tissue types. We are now working towards building an imaging system that can be used in a clinical environment.'

OxEMA is a proposed Isis spinout company seeking investment to take patented OxEMA technology through its initial critical clinical, engineering and regulatory stages. OxEMA is envisaged to have potential non-medical applications which make it even more attractive.

Recent News

04 October 2019

Each pixel in Prophesee’s Metavision sensor only activates if it detects a change in the scene – an event – which means low power, latency and data processing requirements

18 September 2019

3D sensing company, Outsight, has introduced a 3D semantic camera that combines lidar ranging with hyperspectral material analysis. The camera was introduced at the Autosens conference in Brussels

16 September 2019

OmniVision Technologies will be showing an automotive camera module at the AutoSens conference in Brussels from 17 to 19 September, built using OmniVision’s OX03A1Y image sensor with an Arm Mali-C71 image signal processor

09 September 2019

Hamamatsu Photonics claims it is the first company to mass produce a mid-infrared detector that doesn’t use mercury and cadmium, which are restricted under the European Commission’s RoHS directive